Johnson & Johnson joins IMPRESS-Norway
IMPRESS-Norway has been open for inclusion for 3.5 years and so far, more than 2100 patients have had their tumour sequenced through InPreD and more than 430 patients have been offered a new treatment option through this trial. Early results published in Acta Oncologica 1 in May 2024, including data from 186 patients undergoing treatment, …